Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mivebresib (ABBV-075) in advanced cancer
NCT02391480Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2015
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mivebresib in solid tumor, acute myeloid leukemia (AML), multiple myeloma (MM) and 5 more (3 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Tolerated Dose of ABBV-075 at 1 year, Time to Cmax for ABBV-075 at 2 years and 3 more. Started Apr 2015; status: completed.
02
Drugs
mivebresib
03
Conditions
solid tumoracute myeloid leukemia (AML)multiple myeloma (MM)breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02391480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02391480.